Trial Profile

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duvelisib (Primary)
Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms PRIMO
Sponsors Secura Bio; Verastem Oncology

Most Recent Events

27 Apr 2026 According to Secura Bio media release, data from this trial were published in the Journal of Clinical Oncology.
27 Apr 2026 Results presented in the Secura Bio media release.
07 Dec 2025 Results presented at Secura Bio media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com